Liraglutide Reduces Cardiovascular Events and Mortality in Type 2 Diabetes Mellitus Independently of Baseline Low-Density Lipoprotein Cholesterol Levels and Statin Use

Subodh Verma, Lawrence A. Leiter, C. David Mazer, Stephen C. Bain, John Buse, Steven P Marso, Michael Nauck, Bernard Zinman, Heidrun Bosch-Traberg, Søren Rasmussen, Marie M. Michelsen, Deepak L. Bhatt

Research output: Contribution to journalLetter

10 Scopus citations
Original languageEnglish (US)
Pages (from-to)1605-1607
Number of pages3
JournalCirculation
Volume138
Issue number15
DOIs
StatePublished - Oct 9 2018
Externally publishedYes

Keywords

  • diabetes mellitus
  • liraglutide

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

Verma, S., Leiter, L. A., Mazer, C. D., Bain, S. C., Buse, J., Marso, S. P., Nauck, M., Zinman, B., Bosch-Traberg, H., Rasmussen, S., Michelsen, M. M., & Bhatt, D. L. (2018). Liraglutide Reduces Cardiovascular Events and Mortality in Type 2 Diabetes Mellitus Independently of Baseline Low-Density Lipoprotein Cholesterol Levels and Statin Use. Circulation, 138(15), 1605-1607. https://doi.org/10.1161/CIRCULATIONAHA.118.036862